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Abstract 
The purpose was to develop a metastatic score specific to the hepatic and peritoneal site in 
colorectal cancer patients from clinical, pathohistological and molecular markers potentially 
reflecting oncogenic activation (OA) or epithelial-mesenchymal transition (EMT), where OA 
may reflect an activation and EMT the functional loss of certain genes. The primary tumour 
stage (OA, EMT), lymphonodal stage (OA), the presence of a lymphangiosis carcinomatosa 
(OA), histological grade (OA, EMT), and immunoblot extraction of E-cadherin (OA, EMT) 
were differentially rated with zero to one or two points due to their potential contribution 
to each process and the resulting scores were validated in 27 colorectal cancer patients 
(three patients with pre-malignant adenomas, 16 with primaries and two with local recur-
rencies, three of which were metastatic to the peritoneum, six metastatic to the liver and 
two metastatic to both, the liver and the peritoneum, and five with hepatic secondaries, one 
of which at histology was metastatic to the peritoneum too). As a single parameter only the 
N-stage significantly contributed to OA (p<0.05). Median OA and EMT scores, however, 
were 3.5 and 2 in the case of primaries without further spread, 5 and 4 in those nodal posi-
tive, 5 and 4 in the case of peritoneal implants, 6 and 2 in the case of liver metastases, and 
6.5 and 3 in the case of a simultaneous hepatic and peritoneal spread, respectively. These 
differences were significant when scores from patients with and without liver metastases 
(OA, p<0.002) or with peritoneal implants and isolated hepatic spread (EMT, p<0.01) were 
compared. The results suggest a site-specific contribution of OA and EMT to tumour pro-
gression in human colon cancer. 
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Introduction 
Genetic signatures have been employed to de-
termine the site and nature o f  c a n c e r  m e t a s t a s i s . 1,2 
Candidate genes, however, appear to be numerous, 
and frequently do not provide a phenotypic clue. 
Also, oncogenic activation and epithe-
lial-mesenchymal transition have been recognised as 
particular pathways.3,4 In human colon cancer, for 
example, both an activation of the Ki-ras oncogene 
and neoexpression of N-cadherin have been fre-
quently detected,5,6 the first being associated with 
lymphonodal spread and distant metastasis,5 while 
the other has been shown to balance the expression of 
epithelial E-cadherin and to confer EMT and a pre-
disposition to serosal spread.6,7 
Activated Ki-ras has been able to increase the 
expression of E-cadherin.8 EMT, on the other hand, is 
frequently associated with a functional loss of 
E-cadherin but may take place even in the presence of 
normal amounts of E-cadherin protein.6,7,9 OA and 
EMT may therefore refer to dual functions of Int. J. Biol. Sci. 2009, 5 
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E-cadherin as an oncogenic effector and a tumour 
suppressor molecule. Furthermore, a reduced thera-
peutic effectiveness of anti-thyrosine kinase receptor 
monoclonal antibodies in Ki-ras positive colon cancer 
may originate rather up- than downstream from 
Ki-ras, where Ki-ras controls the distribution of small 
GTPase rho proteins and focal adhesion.10 However, 
single factors or genes are rarely attributable to the 
whole process of tumour progression or cancer me-
tastasis. 
Scoring systems have been used to estimate the 
survival benefit of hepatic resection for colon cancer 
liver metastases.11,12 Scoring systems, however, focus-
sing on the primary risk of liver metastasis, do not yet 
exist. And although OA and EMT parameters have 
been correlated with metastatic potential, a perpetual 
lack exists with respect to specific organ sites. In Gas-
trointestinal Stromal Tumours (GIST) we have been 
able to correlate the metastatic site with indicators of 
oncogenic activation. The principle was to use a set of 
clinical and pathohistological parameters represent-
ing the clinical phenotype.13 Here, we propose a 
scoring system to predict the metastatic outcome in 
human colon cancer by focussing on the contributions 
of OA and EMT to hepatic spread or peritoneal dis-
semination. 
Patients and Methods 
Clinical Data, Histology 
Clinical data with respect to tumour extension, 
stage of the primary, grading, and serum CEA were 
retrieved from patient charts and routine pathohis-
tological reports in a series of 27 colorectal cancer pa-
tients of the Surgical Department, University Hospital 
of Freiburg, Germany. Only patients without previous 
radio- and/or chemotherapy were included for at 
least one year. 
The UICC TNM classification14 was used to de-
termine the stage of the disease, and staging or grad-
ing data were retrieved from routine pathology re-
ports. 
Patient follow-up was accomplished over a pe-
riod of 50-56 months by house doctor’s interview in 
the form of a phone call or a written request. 
Specimens 
The use of human materials was approved by 
our institutional review committee. Informed consent 
to participate in the study was obtained from all pa-
tients prior to sample collection.  
Tissue samples (Table 1) were collected from 
surgical specimens (three pre-malignant adenomas, 
17 primary carcinomas, two local recurrencies, and 
seven liver metastases) for immunoblot quantitation 
of cellular E-cadherin protein by dissecting a repre-
sentative anecrotic area from the tumour and from 
adjacent mucosa or liver parenchyma at a distance of 
at least 2 cm from the tumour. Samples were cleaned 
in phosphate-buffered saline (PBS), dissected into 
pieces of 0.1 to 0.2 g, and frozen in liquid nitrogen. 
Fifteen pathology specimens, two from an adenoma, 
11 from primaries (two of which were metastatic to 
the liver and two to the peritoneal site), one from a 
local recurrence attributable to the peritoneal site, and 
one from a liver metastasis, were further processed for 
immunohistochemistry.  
 
 
Table 1. Sample origin for grading and immunoblot ex-
traction of E-cadherin protein 
 n  
primaries 19 
 adenomas  3 
 carcinomas  16 
local recurrences  2 
liver metastases  6 
n, number of patients 
 
Immunoblot Analysis, Immunohistochemistry 
For immunoblot analysis membrane-bound 
protein was extracted in the presence of 1% Triton 
X-100. An equivalent amount of protein was sepa-
rated by 7.5% SDS PAGE electrophoresis and electro-
transferred to 45 μm nitrocellulose membranes, in-
cubated with the primary antibody at 1:1000 for 1.5 
hours and developed using the Western Light 
Chemiluminescent Staining System (Tropix, Bredford, 
Ma., USA). A housekeeping positive control was run 
with every gel. The staining intensity of specific bands 
was quantified using an Imaging Densitometer GS 
710 (BioRad, Göttingen, Germany) and the relative 
staining intensity was calculated relative to adjacent 
normal tissue. 
For immunohistochemistry, formalin-fixed and 
paraffin-embedded tumour samples were cut at 4 μm 
and stained using the multilayer alka-
line-phosphatase-antialkaline phosphatase (APAAP) 
method.15 
In both procedures, the monoclonal antibody 
HECD-1 (Takara Biochemicals, Tokyo, Japan) was 
used for the detection of E-cadherin. 
Development of a Prognostic Score from Clini-
cal, Pathohistological and Molecular Data 
  A score for the estimation of oncogenic activa-
tion (OA) or epithelial-mesenchymal transition (EMT) 
was constructed by differential selection and weigh-Int. J. Biol. Sci. 2009, 5 
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ing of clinical, pathohistological, and molecular pa-
rameters according to their potential contribution to 
the specific process. T-stage, N-stage, pathohistologi-
cal grading, the presence of a lymphangiosis carci-
nomatosa, and immunoblot extraction of E-cadherin 
were assessed as parameters of OA, presumably re-
flecting growth stimulation, extravasation, lymphatic 
arrest, or an activation of differentiation pathways. 
For the examination of EMT, T-stage, pathohistologi-
cal grading, and immunoblot expression of 
E-cadherin were assessed by different means, pre-
sumably reflecting loss of growth control or epithelial 
differentiation (Table 2). Data from immunohisto-
chemistry were not included. 
Suggested factors involved are of genetic, intra-
cellular, extracellular, or intercellular nature, where 
mutated Ki-ras may represent a genetic predisposi-
tion,8,10  snail transcriptional activation controlling 
growth control and apoptotic arrest,9 intergrins and 
cadherin effector molecules mediating cell-matrix and 
intercellular communication,16,17 and 
rac/rho-GTPases intracellular communicators of up- 
and downstream signals,18-20 Ki-ras and E-cadherin 
being predominantly involved in OA, intergrins and 
N-cadherin in EMT, and rac/rho constituting a mo-
lecular switch of both (see below). Tumour stage and 
grading as potential targets of apoptotic arrest and 
growth control were rated higher in the case of EMT 
and the contribution of E-cadherin, although of ad-
vertent nature, in the case of OA. The N-stage and the 
presence of a lymphangiosis carcinomatosa were not 
considered to be relevant consequences of EMT (Table 
2). 
Zero or one point were assigned to the patho-
histological grading and the absence or presence of a 
lymphangiosis carcinomatosa as parameters of OA, as 
well as to immunoblot extraction of E-cadherin as 
parameter of EMT, and zero to two points were as-
signed to the T-stage, N-stage, and immunoblot ex-
traction of E-cadherin as parameters of OA, and the 
grading and T-stage as those of EMT (Table 2). How-
ever, relative immunoblot extraction of E-cadherin 
from a right-sided primary of signet cell type histol-
ogy was rated, although being 0.92 (Table 2), with one 
point for an immunostaining only at the cytoplasmic 
site, and immunoblot extraction of E-cadherin from a 
local recurrence was rated with two points relative to 
other tumour samples on the same blot in place of a 
missing colonic control. 
In the case of liver metastasis, results were 
compared with Fong`s score, which has been pro-
posed to indicate the risk of recurrence subsequent to 
a potential liver resection and which attributes one 
point to each, the time distance between primary and 
hepatic disease <12 months, largest liver nodule >5 
cm, >1 liver nodule, lymphatic spread of the primary, 
and CEA >200 ng/ml, giving rise to a maximum of 5 
points.11 
 
Table 2. Point attribution of single parameters to OA or EMT  
 points  potential  interactions 
  0 1  2  functional molecular1 
OA        
T-stage adenoma  1/2  3/4  ↓growth control, 
apoptotic arrest 
Ki-ras, 
rac, Trk-B 
N-stage 0  1  2  homing  interactions    Ki-ras, 
specific 
T-cells 
lymphangiosis 
carcinomatosa 
no yes  /  ↑invasion, ↓adhesion, ↓anoikis  rac, 
Ki-ras, Trk-B 
grading adenoma, 
1 
2/3 /  cytoskeletal  activation, 
↓growth conrol, 
apoptotic arrest 
rac, 
Ki-ras, 
cadherins, Trk-B 
immunoblot extraction of 
E-cadherin 
T/N<0.1 0.1≤T/N< 
0.33 
T/N≥0.33 clustering, 
functional regulation 
extracellular signals, 
rac, 
Ki-ras 
 
EMT 
      
T-stage adenoma,  1/2  3  4  ↓growth control, 
apoptotic arrest 
snail, twist 
integrins 
grading  adenoma, 1  2  3  dedifferentiation, apoptotic 
arrest 
N-cadherin, 
rho, twist integrins 
immunoblot extraction of 
E-cadherin 
T/N≥0.33 T/N<0,33 
 
- repression  of  transcription 
factors 
N-cadherin, 
rho, snail 
T/N, ratio of E-cadherin protein extraction from tumour and adjacent normal tissue.1 Factors only mentioned in the text are listed. 
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Statistical analysis 
The distribution of patient data and score values 
was determined as the median and range (parenthe-
ses). For the comparison of score values the two-sided 
U-Test according to Wilcoxon, Mann and Whitney 
was used. For correlation analysis of point-attributed 
parameters with patterns of clinical presentation (ab-
sence or presence of secondaries to the hepatic (OA) 
and/or peritoneal (EMT) site) the two-sided 
X2-homogeneity test was used. The relationship be-
tween OA and Fong´s score was determined by the 
use of Spearman´s rank correlation coefficient rs.  
 
 
Results 
Tumour and patient characteristics 
In 27 patients, the median age was 59 (26-78) 
years, the ratio of men to women 16:11. Of 16 patients 
resected for a primary, five presented with synchro-
nous hepatic spread. Follow-up in the remaining 
yielded the detection of metachronous hepatic disease 
in one and no evidence of recurrence in nine. One 
patient of these was not further accessible. Hepatic 
disease of patients admitted for resection was of a 
synchronous nature in two and metachronous in 
three. In two patients, a primary or a local recurrence 
were resected simultaneously with hepatic disease. 
Metachronous hepatic spread occurred at 21 (8-54) 
months from resection of the primary. Local recur-
rencies occurred two times at 13 and 31 months. 
Peritoneal spread was detected in 6 patients (1 x dif-
fuse, 4 x local, and one local recurrence extending into 
the abdominal wall) and a lymphangiosis carcino-
matosa in three. Further staging data and features of 
tumour progression are summarised in Tables 3 and 
4.  
Relative immunoblot extraction of E-cadherin 
was below 0.33 in nine patients, above 0.33 and below 
1.0 in ten, and above or equal 1.0 in eight (Table 5, 
Figure 1A). In the case of samples collected from both 
a primary or local recurrence and a liver metastasis, 
the respective higher relative immunoblot extraction 
of E-cadherin was utilised for the scoring process. 
However, relative immunoblot extraction of 
E-cadherin was comparable in primaries metastatic to 
or secondaries of the liver (data not shown). The size 
of the largest liver nodule was 5 (4-13) cm. Serum 
CEA was 41.7 (2.9-158) ng/ml in patients with hepatic 
disease only, compared to 3.95 (1.3-42.2) in patients 
with peritoneal implants (Table 6). 
Table 3. Clinical and pathohistological staging data of 
primaries 
 n 
T-stage   adenoma  3 
 T1  - 
 T2  1 
 T3  17 
 T4  6 
N-stage   N0  7 
 N1  9 
 N2  8 
site   right hemicolon  11 
 transverse  colon  1 
 left  hemicolon  10 
 rectum  5 
grading adenoma  3 
 1  - 
 2  19 
 3  5 
n, number of patients 
Table 4. Clinical course of colorectal cancer patients 
  n 
local recurrence  2 
lymphangiosis carcinomatosa  3 
peritoneal spread  6 
hepatic spread  13 
n, number of patients 
Table 5. Immunoblot extraction of E-cadherin 
T/N n 
<0.1 2 
≥0.1; <0.33  8 
≥0.33 17* 
T/N, relative extraction of tumour and adjacent normal tissue; n, 
number of patients; * T/N≥1,0: 8 patients 
 
Immunostaining for E-cadherin was predomi-
nantly membranous (Figure 1B). Sometimes, how-
ever, and among two out of three patients with liver 
metastases investigated, a remarkable confocal stain-
ing was observed at the cellular surface (Figure 1B, b 
and d).  
Both, immunoblot extraction and immunohis-
tochemistry were also performed in identical samples 
for the detection of the N-terminus, exon-3 and 
C-terminus of β-catenin (antibodies from Nanotools, 
Teningen, Germany), providing dinstinct results with 
respect to intensity, distribution or subcellular local-
isation. Interestingly, in one patient with diffuse liver 
metastases an N-terminal deletion of β-catenin could 
be observed. However, no detailed correlations ex-
isted with respect to tumour progression and there-
fore these data are not further discussed. 
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Figure 1. Immunoblot extraction (A) of and in-situ staining (B) for E-cadherin of colon cancer (A, lane 1, 3, 5, 7) and 
corresponding mucosal (A, lane 2, 4, 6, 8) samples. Lane 1 and 2, A, and a, B, are from a primary of the descending colon of 
a 66-year-old male, pT4pN0M0G2, T/N 0.97, lane 3 and 4, A, and b, B, are from a cecal primary of a 58-year-old male, 
pT3pN1M1G2 and diffuse liver metastases, T/N 0.5, lane 5 and 6, A, and c, B, are from a sigmoid primary of a 73-year-old 
female, pT4pN1M0G2, T/N 0.1, and lane 7 and 8, A, are from a transverse primary of a 24-year-old male, pT3pN0pM0G3, 
T/N 0.015. d, B is from a synchronous liver metastasis of a 59-year-old male with a left-sided primary, pT3pN1G3. Note that 
in B, dark membranous staining is exclusively due to labelling for E-cadherin. Also, note confocal labelling for E-cadherin in 
b and d, B (arrows). E-cadherin protein in A was run at 120 kD. Bar in B: 40 µm. Samples in B were prestained by H&E. A 
coloured version of B is available in the electronically published journal. T/N, relative extraction of tumour and adjacent 
normal tissue. 
 
 Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
463
Table 6. OA, EMT, and Fong scores of patients metastatic to the hepatic or peritoneal site 
sex, 
age 
TNM-classification 
of primary 
grad-
ing 
metastatic 
site 
synchronous 
/ metachro-
nous 
time in-
terval to 
incidence 
of metas-
tases 
[months] 
number 
of liver 
nodules 
number 
of peri-
toneal 
nodules
size of 
largest 
liver 
nodule 
[cm] 
CEA at 
initial 
presen-
tation  
[ng/ml] 
E-cad. 
T/N 
Fong 
score9
metastatic 
score, 
OA/EMT
w, 59 pT4pN0M1  2  peritoneum synchronous  0    local, 
few 
  4  1,0    4 / 5 
w, 66 pT4pN1M0  3  peritoneum metachronous 13    solid 
tumour
  4  >1,0    5 / 4 
w, 68 pT3pN2M1  2  peritoneum synchronous  0    diffuse    1.3  0    5 / 4 
m, 
66 
pT3pN0M0  2  liver  metachronous 25  multiple    /  /  0,3  /  4 / 3 
m, 
58 
pT3pN0M1  2  liver  synchronous  0  single    4  2.9  1,05  1  5 / 2 
m, 
64 
pT3pN1M0 2  liver  metachronous 16 few   / 4.0  1,52†  2  6 / 2 
m, 
58 
pT3pN1M1  2  liver  synchronous  0  diffuse    -  20  0,5  4  6 / 2 
m, 
59 
pT3pN1M1 2  liver  synchronous  0  few   6.5  41.7  3,83†  3  6 / 2 
m, 
62 
pT3pN1M0 2  liver  metachronous 53 multiple   13  158  0,75†  3  6 / 2 
m, 
58 
pT3pN1M1 2  liver  synchronous  0  single   7 27.4  0,37†  3  6 / 2 
w, 45 pT2pN2M1  2  liver  synchronous  0  single, 
satellites 
 8 130  0,3/1,0† 4  6 / 2 
m, 
56 
pT4pN2M1 2  liver  synchronous  0  single, 
microme-
tastases 
  >5  36.2  0,81  4  7 / 3 
w, 77 pT3pN2M1  2  liver  synchronous  0  multiple    >5  56.5  1,4  4  8 / 2 
m, 
53 
pT3pN2M0 3  liver,  peri-
toneum 
metachronous 8 single  local, 
few 
4.5 11.4  0,17†  1  6 / 4 
w, 59 pT3pN2M0  2  liver, peri-
toneum 
metachronous 21 single  local, 
diffuse 
4 42.2  0,26/ 
0,96† 
1  7 / 2 
w, 75 pT4pN2M1  3  liver, peri-
toneum 
synchronous 0  liver  dif-
fuse 
single  -  3.9  2,0  4  8 / 4 
-, no data because of diffuse hepatic spread; /, no data available; E-cad., immunoblot extraction of E-cadherin; T/N, ratio of tumour to ad-
jacent normal tissue; †, tissue harvest from a hepatic nodule 
 
 
Scoring Results 
As a single parameter, only the N-stage signifi-
cantly correlated with hepatic disease (OA, p<0.05, 
Table 7). However, immunoblot extraction of 
E-cadherin contributed nearly significant to hepatic 
(OA) or tumour size and grade to peritoneal disease 
(EMT) (Table 7). OA scores were significantly higher 
in patients with hepatic spread compared to those 
without, being 6 (4-8) in patients with hepatic spread 
only, or 7 (6-8) in those with hepatic and peritoneal, 
compared to 3.5 (2-5) without tumour spread, 5 (5-7) 
with lymphonodal, and 6 (5-6) with peritioneal spread 
only (p<0.002, Figure 2A). EMT scores on the other 
hand were significantly higher in patients with peri-
toneal implants compared to those with hepatic only, 
being 3 (3-4) in those with peritoneal implants only 
and 4 (3-4) in those with hepatic and peritoneal im-
plants, compared to 2 (2-3) with hepatic implants only 
(p<0.02, Figure 2B). Interestingly, in the case of a he-
patic and peritoneal disease, OA and EMT scores 
were higher compared to those with an isolated he-
patic or peritoneal disease, suggesting a contribution 
of both pathways to this kind of tumour distribution. 
Also, OA and EMT scores were higher in patients 
with an isolated lymphonodal compared to those 
without any tumour spread, being 5 (5-7) compared to 
3.5 (2-5) in the case of OA, and 3 (3-4) compared to 2 
(0-4) in the case of EMT (Figure 2). We also calculated 
the ratio of OA and EMT scores, which was elevated 
particulary in the case of an isolated hepatic spread, 
but, beyond this, did not provide additional informa-
tion (data not shown). 
Fong´s scores, being 3 (1-4) in liver-metastatic 
patients, correlated with those of OA in the case of 
hepatic disease only (rs=0.830, p<0.005, data available 
from 9 patients) or if additional peritoneal disease was 
included (rs=0.622, p<0.025, 12 patients) (Table 6). 
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Table 7. Contribution of single parameters of OA and EMT 
to liver metastasis or peritoneal spread, respectively 
  OA EMT 
  X2  FG X2 FG 
T-stage 1.07  1  3.88  2 
N-stage 6,93  2 / / 
grading -  - 5.44  2 
lymphangiosis 
carcinomatosa 
- -  /  / 
Immunoblot ex-
traction of 
E-cadherin 
2,45 1  0,39 1 
Critical p-values (p<0.05), FG = 1: 3.84, FG = 2: 5.99; FG, freedom 
grade; -, no calculation available for the reason of parameter dis-
tribution; /, not determined 
 
 
 
 
Figure 2. Score values in patients without, and with lym-
phonodal, peritoneal, hepatic, or both peritoneal and he-
patic spread. Median, range, number of patients. A, OA; B, 
EMT. 
Discussion 
In human colorectal cancer, the metastatic out-
come can be easily studied because of its almost ex-
clusive portal-venous drainage into the liver sinusoid. 
The liver represents an organ of entodermal origin too 
and this may account for a preferred homing of epi-
thelially derived cancer cells. Dissemination towards 
the serosal site, however, may simply take place by 
detaching cancer cells. 
Our results suggest a differential contribution of 
clinical, pathohistological and molecular parameters 
to hepatic or peritoneal spread in colorectal cancer. 
OA scores were significantly higher in patients with 
liver metastases compared to those without and EMT 
scores were significantly higher in patients with 
peritoneal implants compared to those with an iso-
lated hepatic spread. A simultaneous employment of 
OA and EMT was suggested in patients with lym-
phonodal, or a combined peritoneal and hepatic 
spread. Finally, the existence of a lymphangiosis car-
cinomatosa may reveal a particular feature of cellular 
activation with respect to vascular invasion, adhesion 
and dissemination. 
On a molecular level, the flip sides of OA and 
EMT may well be demonstrated by the antagonistic 
functions of rac and rho.18,19 Rac controls rho and focal 
adhesion in a dominant fashion.18 This, in turn, con-
stitutes a direct link towards organ metastasis, which 
has been shown to be of a dominant nature too.21 Ac-
tivation of Rac induces focal accumulation of 
E-cadherin protein at the membranous site and con-
tributes to cadherin-mediated crosstalk of cells,18,20 
adhesive plasticity and eventually to a successful 
homing within the liver parenchyma. Activation of 
rho, however, has rather been attributed to a loss of 
cellular adhesion and EMT.   
In experimental mouse tumour systems, mo-
lecular markers of OA and MT have been implicated 
in the metastatic process. Thus, an activation of the 
Thyrosinkinase TrkB3 (OA) or of the transcription 
factor twist4 (EMT) were able to induce liver and lung 
metastasis, in support of our finding that activation of 
both pathways may contribute to the metastatic 
process at different organ sites. Also, TrkB, Ki-ras, and 
twist did all contribute to an interruption of apoptotic 
pathways,3,4,8 suggesting thereby an interaction with 
tumour size and grade.  
Lymphonodal spread of the primary and serum 
CEA have been identified as predictors for the out-
come from resection of hepatic metastases.11,12 Indeed, 
the concentrations of CEA and those of soluble serum 
E-cadherin correlated in patients with colorectal liver 
metastases.22 A significant correlation between OA´ Int. J. Biol. Sci. 2009, 5 
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and Fong´s scores, the latter of predicting the risk of 
recurrence subsequent to hepatic resection, further 
demonstrates the robustness of such scores incorpo-
rating easily accessible clinical results. However, the 
exact molecular pathways of CEA shedding are not 
yet understood and we therefore decided to not in-
clude CEA into the scoring process. 
Recently, Landemaine et al. identified genes 
coding for β8-integrin and P-cadherin as part of a 
signature to contribute to breast cancer lung metasta-
sis, thereby stressing the environmental question for a 
successful homing of tumour cells.1 However, clinical, 
pathohistological, and cellular markers are also likely 
to represent the metastatic significance of varying 
genes.  
While hepatic organ metastasis may require the 
activation of differentiation pathways, metastasis to 
the peritoneal surface may rather be associated with 
patterns of epithelial-mesenchymal transition. Finally, 
the lymphonodal environment may be additionally 
determined by organ-specific lymphocytes. Although 
statistical correlations of single genes are informative, 
we also suggest linking site-specificity to patterns of 
clinical and phenotypic presentation in order to meet 
the homing requirements of a specific organ site. 
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